Now, we have been discussing the promise of biosimilars to lower the cost in a market oriented, competitive way.
Bill Cassidy: “Now, we have been discussing the promise of biosimilars to lower the cost in a market oriented, competitive way.”
On the recordFebruary 7, 2024
Source
congress.govEditor's note · Context
Cassidy emphasizes the potential of biosimilars to reduce drug costs without government regulation.
Share
More from Bill Cassidy
Sep 24, 2026
You’ll also need to ensure that uninformed ideologies do not influence FDA’s decisions on whether to approve individual products, even if the president is pressuring you.
Sep 24, 2026
That executive order was based on zero scientific evidence and would require parents to spend more time and more money taking their children to medical appointments to receive vaccine shots.
Oct 3, 2026
At a time when hostile actors are increasingly using sophisticated tactics to breach health care systems, the Health Care Cybersecurity and Resilience Act will help health care providers strengthen their defenses against cyber threats and…





